BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18614198)

  • 1. Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors.
    Adams H; Tzankov A; d'Hondt S; Jundt G; Dirnhofer S; Went P
    Hum Pathol; 2008 Sep; 39(9):1323-30. PubMed ID: 18614198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
    Braaten KM; Betensky RA; de Leval L; Okada Y; Hochberg FH; Louis DN; Harris NL; Batchelor TT
    Clin Cancer Res; 2003 Mar; 9(3):1063-9. PubMed ID: 12631608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immunophenotypic and molecular study of primary large B-cell lymphoma of bone.
    Huebner-Chan D; Fernandes B; Yang G; Lim MS
    Mod Pathol; 2001 Oct; 14(10):1000-7. PubMed ID: 11598170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype.
    Heyning FH; Hogendoorn PC; Kramer MH; Holland CT; Dreef E; Jansen PM
    J Clin Pathol; 2009 Sep; 62(9):820-4. PubMed ID: 19734480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas.
    Hallermann C; Niermann C; Fischer RJ; Schulze HJ
    J Am Acad Dermatol; 2007 Apr; 56(4):588-97. PubMed ID: 17289214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
    Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
    Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
    Jang KY; Hwang SH; Kwon KS; Kim KR; Choi HN; Lee NR; Kwak JY; Park BH; Park HS; Chung MJ; Kang MJ; Lee DG; Kim HS; Shim H; Moon WS
    Am J Surg Pathol; 2008 Oct; 32(10):1523-31. PubMed ID: 18724249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
    Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
    Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite a non-germinal center B-cell-like phenotype.
    Sato Y; Onishi N; Morito T; Takata K; Mizobuchi K; Nagatsuka H; Ichimura K; Tanaka T; Tamura M; Yoshino T
    Cancer Sci; 2009 Jan; 100(1):42-6. PubMed ID: 19018759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of prognostic factors in 74 cases of diffuse large B-cell lymphoma].
    Wang J; Ke XY; Zhao LZ; Li M; Jing HM; Wang JJ; Zhao W; Gao ZF
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):667-70. PubMed ID: 18399171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perforation predicts poor prognosis in patients with primary intestinal diffuse large B-cell lymphoma.
    Chuang SS; Ye H; Yang SF; Huang WT; Chen HK; Hsieh PP; Hwang WS; Chang KY; Lu CL; Du MQ
    Histopathology; 2008 Oct; 53(4):432-40. PubMed ID: 18983608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma.
    Eser B; Sari I; Canoz O; Altuntas F; Cakmak E; Ozturk A; Ozkan M; Er O; Cetin M; Unal A
    Am J Hematol; 2006 May; 81(5):307-14. PubMed ID: 16628716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study.
    Connor J; Ashton-Key M
    Histopathology; 2007 Nov; 51(5):697-703. PubMed ID: 17927592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
    Grange F; Beylot-Barry M; Courville P; Maubec E; Bagot M; Vergier B; Souteyrand P; Machet L; Dalac S; Esteve E; Templier I; Delaporte E; Avril MF; Robert C; Dalle S; Laroche L; Delaunay M; Joly P; Wechsler J; Petrella T
    Arch Dermatol; 2007 Sep; 143(9):1144-50. PubMed ID: 17875875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.